CJC-1295 No DAC & Ipamorelin Research Reporting Standards

For a wholesale buyer, the reporting standard for these two compounds reduces to four documented items per lot: identity confirmed analytically, purity quantified by a disclosed HPLC method, net peptide content stated separately from vial fill weight, and a contamination panel tied to the same lot number printed on the vial. If a supplier cannot show all four on a certificate of analysis you can open and read yourself, you are buying a claim rather than a specification. Everything below covers how to read those documents, what makes these two molecules easy or hard to verify, and what belongs in your own file once the boxes land. All compounds discussed here are research use only and are not FDA-approved drugs.

Why these two get documented as a pair

CJC-1295 No DAC and Ipamorelin are structurally unrelated but operate on the same axis in laboratory models, which is why research groups order them together, store them together, and — too often — log them together under a single sloppy record. CJC-1295 without the drug affinity complex is a modified GRF(1-29) analog: a 29-residue growth-hormone-releasing-hormone fragment carrying substitutions intended to slow enzymatic degradation. Ipamorelin is a short synthetic pentapeptide studied as a selective ghrelin-receptor agonist. Research suggests the two act through distinct receptor pathways, which is the usual rationale for examining them in parallel rather than in isolation.

The documentation consequence is naming drift. "CJC-1295" is used in the literature and in commerce for two different molecules — the DAC-conjugated version and the DAC-free modified GRF(1-29). "Mod GRF 1-29", "CJC-1295 DAC-free" and "CJC-1295 No DAC" circulate as synonyms for the same compound. A defensible certificate of analysis names the exact analog and states the sequence, and whatever catalog or registry identifiers the manufacturer uses should read identically across the COA, the vial label, the packing slip and the invoice. When those four documents disagree, you cannot prove what is in your inventory, regardless of how good the underlying material is.

Ipamorelin creates the opposite problem. Short peptides are comparatively cheap to synthesize, and a five-residue chain gives a counterfeiter very little to get wrong on appearance alone. Nothing about a white lyophilized cake distinguishes correct material from a truncated or substituted analog. Only analysis does, and only analysis performed on the lot in your hands.

What a lot-level certificate of analysis has to contain

A COA that supports a purchasing decision is lot-specific, dated, and attributable to a named laboratory or analyst. Product-level COAs — one document reused across every batch ever made — tell you what the supplier intends to produce, not what they produced this time.

Identity. Mass spectrometry confirming that the observed mass matches the theoretical mass for the stated sequence. For CJC-1295 No DAC, the substituted residues are exactly what identity testing is meant to confirm; an unmodified GRF fragment is a different molecule with different stability behaviour.

Purity. Reverse-phase HPLC reported as area percent, with the method summarized: column chemistry, mobile phase, gradient profile, detection wavelength, run time. A percentage without a method is not a measurement, because area percent is only meaningful under stated conditions.

Content. Net peptide content is not the same number as the amount of powder in the vial. Synthetic peptides are typically isolated as salts — commonly acetate or trifluoroacetate — and carry residual water. A vial labeled 10mg may contain 10mg of gross fill or 10mg of net peptide, and the difference is material when you are comparing quotes across suppliers. The COA should say which figure it reports.

Contamination panels. Water content, residual solvents, bioburden and bacterial endotoxin, and heavy metals are the categories buyers most often look for. Which panels are appropriate depends on the material and the intended laboratory application, but the panel list should be stated rather than implied.

Traceability. Lot number, manufacture date, retest or expiry date, storage conditions, and the signature or identifier of whoever released the lot.

Document-by-document: what each one proves

Reading a chromatogram without taking it on faith

Area percent is a relative measure. It tells you what proportion of the UV-absorbing material eluting during that run sat under the main peak — nothing more. A gradient run too quickly compresses closely related substances into the main peak and flatters the result. A single detection wavelength can under-represent impurities that absorb poorly at that wavelength. This is not an accusation against any particular supplier; it is the reason method disclosure is the difference between a number and a result.

Mass spectrometry confirms mass, which is powerful but not total. Isobaric errors — a substitution or rearrangement that preserves the molecular weight, or stereochemical racemization at a residue — can pass a mass check while altering the molecule. That is why identity and purity are read together rather than one standing in for the other, and why the sequence should be printed on the document rather than assumed from the product name.

Three practical checks take under a minute each. First, does the lot number on the COA match the lot number on the vial in front of you, character for character? Second, does the analysis date precede your ship date, or was the document generated from a much older batch? Third, is the document a flat image of a table, or does it include the underlying trace? Suppliers who publish the full analytical package are making an auditable statement. Suppliers who publish a summary table are asking for trust.

Recordkeeping on your side of the transaction

Supplier documentation is only half of a reporting standard. The other half is what your business does with it, and this is the part most new wholesale buyers underbuild.

Keep an inbound lot log: date received, compound, lot number, quantity, condition on arrival, and a stored copy of the COA as it existed on the day you bought. Public COA libraries are a strength, but a link is not a record — download the PDF. If material moves on to another business, your log should let you answer the only question that matters in a recall or dispute: which lots went where, and when.

Store lyophilized material as the COA specifies, protected from heat, light and moisture, and note any temperature excursion in transit rather than letting it disappear. Label and shelve research-use-only inventory so it is physically and visually separated from anything a customer or visitor could mistake for consumer product. Maintain a short deviation log — damaged vials, mismatched paperwork, documents that never arrived — because a pattern across lots is information your purchasing decision should reflect, and because a written record is worth far more than a recollection twelve months later.

Finally, decide who owns this. Documentation standards fail when they belong to everyone. One named person approving inbound lots against their COAs is worth more than a written policy nobody executes.

The questions that belong with counsel, not with your supplier

How research-use-only materials may be purchased, held, transferred or resold is a legal question shaped by your entity type, your licensing posture, your state, and the specific nature of your work. It is not a question a supplier can answer for you, and any supplier who offers a confident conclusion about your obligations is answering outside their competence.

The useful move is to bring your attorney a list of questions rather than a conclusion: What is our regulatory status for holding these materials? What labeling and storage obligations attach to us specifically? What are we permitted to say in writing to our own buyers? Are there state board notification or registration questions we should resolve before the first order? Do our records satisfy whatever retention expectations apply to us? Requirements vary by jurisdiction and change over time — check with your state board and your own counsel rather than relying on general guidance, including this article. This is informational content, not legal advice.

If any of the work downstream involves animal models, the attending veterinarian on your protocol belongs in that conversation as well — talk to your veterinarian and your institutional review committee before a study design is finalized, and keep their written sign-off with the lot file.

What Real Peptides does differently

Real Peptides publishes what most of this article asks you to demand. Purity is specified at 99%+ by HPLC. Every batch runs through 7-panel testing, and the certificates of analysis are publicly verifiable — you can pull up the lab results yourself, before you place an order and again after it arrives, rather than requesting them from a sales representative or paying for them as an add-on. That last point is the practical divide in this market. A supplier who publishes COAs openly has accepted that any buyer, competitor or skeptic can audit the claim. A supplier who gates documentation, charges for it, or answers purity questions with a number instead of a document has chosen the opposite posture, and you should price that difference in.

Fulfillment runs from the US in 5–7 days, which matters for documentation as much as for speed: shorter, domestic transit means fewer handoffs to reconstruct if a shipment arrives in unexpected condition. Wholesale pricing is presented as tiers rather than negotiated case by case behind a contact form, so you can model unit economics before committing. Margins and program economics vary widely with volume and category, and any supplier quoting you a specific return is guessing.

Onboarding runs as a 3-step wholesale application: apply, verify your business, and get access to partner pricing across the catalog. Every compound in that catalog, including the two discussed here, is supplied for laboratory research use only and is not for human consumption.

If your business buys research compounds regularly and you are tired of chasing paperwork after the fact, the Wholesale Partner Program application is the next step — it takes a few minutes, and the COAs are readable before you ever apply.

You can review the lot documentation for CJC-1295 No DAC 10mg and Ipamorelin 10mg directly, compare them against related compounds such as Tesamorelin 10mg, browse the wider growth factor and tissue signaling research category, and see the full program at Real Peptides.